Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response

Pharmacogenomics

Volumn 12, Issue 2, 2011, Pages 277-291

  Hwang, Rudi ^a   Souza, Renan P ^a   Tiwari, Arun K ^a   Zai, Clement C ^a   Müller, Daniel J ^a   Potkin, Steven G ^b   Lieberman, Jeffrey A ^c   Meltzer, Herbert Y ^d   Kennedy, James L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antipsychotic response; association study; clozapine response; dopamine receptor gene; gene gene interaction; GRIN1; GRIN2A; GRIN2B; NMDA receptor subunit gene; schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SERINE;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; ARTICLE; CAUCASIAN; DNA POLYMORPHISM; DRUG RESPONSE; EFFECT SIZE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CLOZAPINE; EPISTASIS, GENETIC; GENETIC ASSOCIATION STUDIES; HUMANS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79951920911     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.182     Document Type: Article

References (97)

1. Kane JM: The current status of neuroleptic therapy. J. Clin. Psychiatry 50(9), 322-328 (1989).
2. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158(4), 518-526 (2001).
3. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
4. Meltzer HY: Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14(1), 1-20 (1997).
5. Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry 156(7), 990-999 (1999).
6. Leysen JE: Receptor profile of antipsychotics. In:Atypical Antipsychotics , Ellenbroek BA, Cools AR (Eds). Bikhauser Verlag, Basel, Switzerland, 57-81 (2000).
7. Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry 20(1), 15-27 (2005).
8. Deutch AY, Clark WA, Roth RH: Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521(1-2), 311-315 (1990).
9. Meyer-Lindenberg A, Miletich RS, Kohn PD et al.: Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5(3), 267-271 (2002).
10. Pycock CJ, Kerwin RW, Carter CJ: Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286(5768), 74-76 (1980).
11. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44(7), 660-669 (1987).
12. Joyce JN, Lexow N, Bird E, Winokur A: Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in huntington's disease and schizophrenia. Synapse 2(5), 546-557 (1988).
13. Hwang R, Shinkai T, De Luca V et al.: Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl.) 181(1), 179-187 (2005). Rationale and single polymorphism association results for DRD2 polymorphisms used in the present study.
14. Hwang R, Shinkai T, De Luca V et al.: Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J. Psychopharmacol. 21(7), 718-727 (2007). Detailed description of the clinical sample, rationale and single polymorphism association results for DRD1 polymorphisms used in the present study.
15. Hwang R, Zai C, Tiwari A et al.: Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 10(3), 200-218 (2009). Rationale and single polymorphism association results for DRD3 polymorphisms used in the present study.
16. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP: Anti-glutamatergic effects of clozapine. Neurosci. Lett. 163(2), 155-158 (1993).
17. Wang RY, Liang X: M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19(1), 74-85 (1998).
18. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY: Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283(1), 226-234 (1997).
19. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148(10), 1301-1308 (1991).
20. Olney JW, Farber NB: Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52(12), 998-1007 (1995).
21. Tamminga CA, Holcomb HH, Gao XM, Lahti AC: Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions. Int. Clin. Psychopharmacol. 10(Suppl. 3), 29-37 (1995).
22. Duncan GE, Moy SS, Lieberman JA, Koller BH: Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology (Berl.) 184(2), 190-200 (2006).
23. Levin ED, Caldwell DP, Perraut C: Clozapine treatment reverses dizocilpine-induced deficits of pre-pulse inhibition of tactile startle response. Pharmacol. Biochem. Behav. 86(3), 597-605 (2007).
24. Beraki S, Kuzmin A, Tai F, Ogren SO: Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol. Eur. Neuropsychopharmacol. 18(7), 486-497 (2008).
25. Farber NB, Foster J, Duhan NL, Olney JW: Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21(1), 33-37 (1996).
26. Farber NB, Price MT, Labruyere J et al.: Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry 34(1-2), 119-121 (1993).
27. Gaisler-Salomon I, Diamant L, Rubin C, Weiner I: Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology (Berl.) 196(2), 255-267 (2008).
28. Olney JW: New mechanisms of excitatory transmitter neurotoxicity. J. Neural. Transm. Suppl. 43, 47-51 (1994).
29. Olney JW, Farber NB: Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J. Clin. Psychiatry 55(Suppl. B), 43-46 (1994).
30. Zhang W, Pouzet B, Jongen-Relo AL, Weiner I, Feldon J: Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics. Neuroreport 10(12), 2533-2538 (1999).
31. Corbett R, Camacho F, Woods AT et al.: Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonistinduced behaviors. Psychopharmacology (Berl.) 120(1), 67-74 (1995).
32. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A: Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 27(Suppl. A), S16-S24 (2005). Functional interactions between glutamatergic and dopamine elements unify the key alterations postulated in schizophrenia.
33. Carlsson A, Hansson LO, Waters N, Carlsson ML: A glutamatergic deficiency model of schizophrenia. Br. J. Psychiatry Suppl. (37), 2-6 (1999).
34. Kegeles LS, Abi-Dargham A, Zea-Ponce Y et al.: Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 48(7), 627-640 (2000).
35. Lee SP, So CH, Rashid AJ et al.: Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 279(34), 35671-35678 (2004).
36. O'Dowd BF, Ji X, Alijaniaram M et al.: Dopamine receptor oligomerization visualized in living cells. J. Biol. Chem. 280(44), 37225-37235 (2005).
37. So CH, Varghese G, Curley KJ et al.: D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol. Pharmacol. 68(3), 568-578 (2005).
38. Rashid AJ, So CH, Kong MM et al.: D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl Acad. Sci. USA 104(2), 654-659 (2007).
39. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C: Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 74(1), 59-69 (2008).
40. Marcellino D, Ferre S, Casado V et al.: Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem. 283(38), 26016-26025 (2008).
41. Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU: Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J. Neurochem. 87(3), 631-641 (2003).
42. Novi F, Millan MJ, Corsini GU, Maggio R: Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. J. Neurochem. 102(4), 1410-1424 (2007).
43. Scarselli M, Novi F, Schallmach E et al.: D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276(32), 30308-30314 (2001).
44. Lee FJ, Xue S, Pei L et al.: Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111(2), 219-230 (2002).
45. Fiorentini C, Gardoni F, Spano P, Di Luca M, Missale C: Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J. Biol. Chem. 278(22), 20196-20202 (2003).
46. Liu XY, Chu XP, Mao LM et al.: Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52(5), 897-909 (2006).
47. Dziedzicka-Wasylewska M, Faron-Gorecka A, Gorecki A, Kusemider M: Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization - a working hypothesis. Pharmacol. Rep. 60(5), 581-587 (2008).
48. Faron-Gorecka A, Gorecki A, Kusmider M, Wasylewski Z, Dziedzicka-Wasylewska M: The role of D1-D2 receptor heterodimerization in the mechanism of action of clozapine. Eur. Neuropsychopharmacol. 18(9), 682-691 (2008).
49. Monyer H, Sprengel R, Schoepfer R et al.: Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256(5060), 1217-1221 (1992).
50. Dingledine R, Borges K, Bowie D, Traynelis SF: The glutamate receptor ion channels. Pharmacol. Rev. 51(1), 7-61 (1999).
51. Kutsuwada T, Kashiwabuchi N, Mori H et al.: Molecular diversity of the NMDA receptor channel. Nature 358(6381), 36-41 (1992).
52. Vojvoda D, Grimmell K, Sernyak M, Mazure CM: Monozygotic twins concordant for response to clozapine. Lancet 347(8993), 61 (1996).
53. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ: Association analysis for NMDA receptor subunit 2b (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr. Genet. 11(4), 219-222 (2001).
54. Moore JH: The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum. Hered. 56(1-3), 73-82 (2003). Gene-gene interaction is a ubiquitous component of the genetic architecture of common human diseases and complex interactions are more important than the independent main effects of individual susceptibility genes.
55. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E: Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 14(5), 303-307 (2004).
56. Choudhry S, Que LG, Yang Z et al.: GSNO reductase and b2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet. Genomics 20(6), 351-358 (2010).
57. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th Edition. American Psychiatric Association, Washington, DC, USA (1994).
58. Hwang R, Shinkai T, Deluca V et al.: Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur. Neuropsychopharmacol. 16(4), 248-259 (2006).
59. Lahiri DK, Nurnberger JI Jr.: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19(19), 5444 (1991).
60. Begni S, Moraschi S, Bignotti S et al.: Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol. Psychiatry 53(7), 617-619 (2003).
61. Galehdari H, Pooryasin A, Foroughmand A, Daneshmand S, Saadat M: Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population. J. Mol. Neurosci. 38(2), 178-181 (2009).
62. Georgi A, Jamra RA, Klein K et al.: Possible association between genetic variants at the GRIN1 gene and schizophrenia with lifetime history of depressive symptoms in a German sample. Psychiatr. Genet. 17(5), 308-310 (2007).
63. Martucci L, Wong AH, Trakalo J et al.: N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case-control analyses. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 119B(1), 24-27 (2003).
64. Zhao X, Li H, Shi Y et al.: Significant association between the genetic variations in the 5′ end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol. Psychiatry 59(8), 747-753 (2006).
65. Itokawa M, Yamada K, Yoshitsugu K et al.: A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2a subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13(5), 271-278 (2003). Promotor activity of plasmid constructs with repeat lengths of 25 or more were significantly lower than those with less than 25 repeats.
66. Iwayama-Shigeno Y, Yamada K, Itokawa M et al.: Extended analyses support the association of a functional (GT)n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci. Lett. 378(2), 102-105 (2005).
67. Miyatake R, Furukawa A, Suwaki H: Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol. Psychiatry 7(10), 1101-1106 (2002). Luciferase reporter activity of plasmids with the GRIN2B T-200G T allele were significantly upregulated compared with that of the G allele.
68. Martucci L, Wong Ah, De Luca V et al.: N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr. Res. 84(2-3), 214-221 (2006).
69. Potkin SG, Basile VS, Jin Y et al.: D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol. Psychiatry 8(1), 109-113 (2003).
70. Huang W, Li MD: Differential allelic expression of dopamine D1 receptor gene (DRD1) is modulated by microRNA mir-504. Biol. Psychiatry 65(8), 702-705 (2009).
71. Duan J, Wainwright MS, Comeron JM et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12(3), 205-216 (2003).
72. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J: C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63(10), 907-912 (2009).
73. Arinami T, Gao M, Hamaguchi H, Toru M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6(4), 577-582 (1997).
74. Jonsson EG, Nothen MM, Grunhage F et al.: Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4(3), 290-296 (1999).
75. Malhotra AK, Buchanan RW, Kim S, Kestler L, Breier A, Pickar D, Goldman D: Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. J. Sch. Res. 36(1-3), 2 (1999).
76. Noble EP: The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 16(1), 33-45 (1998).
77. Ritchie T, Noble EP: Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem. Res. 28(1), 73-82 (2003).
78. Thompson J, Thomas N, Singleton A et al.: D2 dopamine receptor gene (DRD2) Taq1a polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6), 479-484 (1997).
79. Pohjalainen T, Rinne JO, Nagren K et al.: The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3(3), 256-260 (1998).
80. Jeanneteau F, Funalot B, Jankovic J et al.: A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc. Natl Acad. Sci. USA 103(28), 10753-10758 (2006).
81. Lundstrom K, Turpin MP: Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki forest virus system. Biochem. Biophys. Res. Commun. 225(3), 1068-1072 (1996).
82. Hellstrand M, Danielsen EA, Steen VM, Ekman A, Eriksson E, Nilsson CL: The Ser9Gly SNP in the dopamine D3 receptor causes a shift from camp related to PGE2 related signal transduction mechanisms in transfected CHO cells. J. Med. Genet. 41(11), 867-871 (2004).
83. Jonsson EG, Flyckt L, Burgert E et al.: Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr. Genet. 13(1), 1-12 (2003).
84. Labrie V, Lipina T, Roder JC: Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl.) 200(2), 217-230 (2008).
85. Gu WH, Yang S, Shi WX, Zhen XC, Jin GZ: Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine. Acta. Pharmacol. Sin. 28(7), 953-958 (2007).
86. Fradley RL, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS: STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain. Res. 163(2), 257-264 (2005).
87. Humphries C, Mortimer A, Hirsch S, De Belleroche J: NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7(12), 2051-2055 (1996).
88. Meador-Woodruff JH, Healy DJ: Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev. 31(2-3), 288-294 (2000).
89. Mohn AR, Gainetdinov RR, Caron MG, Koller BH: Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98(4), 427-436 (1999).
90. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T: Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor e1 subunit. J. Neurosci. 21(2), 750-757 (2001).
91. Angers S, Salahpour A, Bouvier M: Dimerization: an emerging concept for g protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42, 409-435 (2002). Property of receptors is to form heterodimeric complexes with novel pharmacological, signaling and trafficking characteristics.
92. Abi-Dargham A, Moore H: Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9(5), 404-416 (2003).
93. Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ: Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism. Relat. Disord. 15(Suppl. 4), S2-S7 (2009).
94. George SR, O'Dowd BF: A novel dopamine receptor signaling unit in brain: heterooligomers of D1 and D2 dopamine receptors. ScientificWorldJournal 7, 58-63 (2007).
95. Lidow MS: Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res. Brain Res. Rev. 43(1), 70-84 (2003).
96. Cordell HJ: Detecting gene-gene interactions that underlie human diseases. Nat. Rev. Genet. 10(6), 392-404 (2009). Utility and challenges in methods for detection and assessment of statistical gene-gene interactions.
97. Buchner A, Erdfelder E, Faul F: How to Use G*Power [WWW document] (1997) www.psycho.uni-duesseldorf.de/aap/projects/gpower/how-to-use-gpower.html